Effects of tumour necrosis factor-α on the coronary circulation of the rat isolated perfused heart: A potential role for thromboxane A2 and sphingosine

British Journal of Pharmacology

Volumn 124, Issue 3, 1998, Pages 493-498

  Edmunds, N J ^a   Woodward, B ^a  

^a University of Bath   (United Kingdom)

Author keywords

Coronary circulation; Endothelin; GR32191; Indomethacin; N oleoylethanolamine; Sphingosine; Thromboxane A2; TNF ; Vasoconstriction; ZD1542

Indexed keywords

6 [2 [1 METHYL 1 (2 NITRO 4 TOLYLOXY)ETHYL] 4 (3 PYRIDYL) 1,3 DIOXAN 5 YL] 4 HEXENOIC ACID; BOSENTAN; ENDOTHELIN; ETHANOLAMINE DERIVATIVE; INDOMETACIN; PHOSPHOLIPASE A2; PROSTANOID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VAPIPROST;

ANIMAL TISSUE; ARTERY TONE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; ISOLATED HEART; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT;

ANIMALS; CORONARY CIRCULATION; ETHANOLAMINES; HEART; INDOMETHACIN; MALE; MYOCARDIUM; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; SPHINGOSINE; SULFONAMIDES; THROMBOXANE A2; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION;

EID: 0031800520     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701863     Document Type: Article

References (45)

1. ATKINSON, Y.H., MURRAY, A.W., KRILIS, S., VADAS, M.A. & LOPEZ, A.F. (1990). Human tumour necrosis factor-alpha (TNF-α) directly stimulates arachidonic acid release in human neutrophils. Immunology, 70, 82-87.
2. 2 production and sphingomyelin metabolism. J. Biol. Chem., 28, 20044-20050.
3. BEUTLER, B., MILSARK, J. & CERAMI, A. (1985). Passive immunisation against cachectin/tumour necrosis factor from lethal effect of endotoxin. Science, 229, 869-871.
4. 2 biosynthesis in endotoxin induced intestinal damage in the rat. Prostaglandins, 38, 319-333.
5. 2+ release from mitochondria. J. Biol. Chem., 260, 105-113.
6. 2 synthase inhibitor and receptor antagonist in vitro. Br. J. Pharmacol., 110, 1600-1606.
7. 2 fragments and rosarinic acid. Br. J. Pharmacol., 84, 317-327.
8. 2 production. J. Pharmacol. Exp. Ther., 225, 94-101.
9. CAMUSSI, G., ALBANO, E., TETTA, C. & BUSSOLINO, F. (1991). The molecular action of tumor necrosis factor-α. Eur. J. Biochem., 202, 3-17.
10. 2 production in human fibroblasts. J. Exp. Med., 174, 1363-1369.
11. 2 antagonist SQ29,548 impair in vitro contractions of aortic rings of ex vivo treated lipopolysaccharide rats. J. Lipid. Med., 13, 177-187.
12. 2-activating protein in endothelial cells. Biochem. J., 250, 125-132.
13. CLOZEL, M., BREU, V., GRAY, G.A., KALINA, B., LOFFER, B.M., BURRI, K., CASSAL, J.M., HIRTH, G., MULLER, M., NEIDHART, W. & RAMUZ, H. (1994). Pharmacological characterisation of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther., 270, 228-235.
14. CORONEOS, E., MARTINEZ, M., MCKENNA, S. & KESTER, M. (1995). Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. J. Biol. Chem., 270, 23305-23309.
15. DRESSLER, K.A., MATHIAS, S. & KOLESNICK, R.N. (1992). Tumor necrosis factor-α activates the sphingomyelin signal transduction pathway in a cell free system. Science, 255, 1715-1718.
16. EDMUNDS, N.J. & WOODWARD, B. (1997). Effects of TNFα on insulin action in the isolated rat heart. J. Mol. Cell. Cardiol., 29, Fr57.
17. ELIAS, J.A., GUSTILLO, K., BAEDER, W. & FREUNDLICH, B. (1987). Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J. Immunology. 138, 3812-3816.
18. 2+ release from mitochondria by N-acylethanolamines, a class of lipid synthesized in ischaemic heart tissue. J. Biol. Chem., 257, 1383-1391.
19. FLETCHER, J.R. & RAMWELL, P.W. (1977). Modification, by asprin and indomethacin, of the haemodynamic and prostaglandin releasing effects of E. coli endotoxin in the dog. Br. J. Pharmacol., 61, 175-181.
20. GODFREY, R.W., JOHNSON, W.J. & HOFFSTEINN, S.T. (1987). Recombinant tumor necrosis factor and interleukin-1 both stimulate human synovial cell arachidonic acid release and phospholipid metabolism. Biochem. Biophys. Res. Commun., 142, 235-241.
21. HANNUN, Y.A. (1994). The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem., 269, 3125-3128.
22. 2 is crucial in the cytotoxic action of tumor necrosis factor. J. Biol. Chem., 268, 11290-11295.
23. HOHLFELD, T., KLEMM, P., THIEMERMANN, C., WARNER, T.D., SCHROR, K. & VANE, J.R. (1995). The contribution of tumour necrosis factor-α and endothelin-1 to the increase in coronary resistance in hearts from rats treated with endotoxin. Br. J. Pharmacol., 116, 3309-3315.
24. JAYADEV, S., LINARDIC, C.M. & HANNUN, Y.A (1994). Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor α. J. Biol. Chem., 269, 5757-5763.
25. KATZ, A.M. (1992). Structure of the heart and cardiac muscle. In: Physiology of the Heart. pp. 1 -36. ed. Katz, A.M. New York: Raven Press.
26. KENGATHARAN, M., BATTISTINI, B., WARNER, T.D., THIEMERMANN, C. & VANE, J.R. (1995). Endothelin-1 mediates the increase in ex vivo coronary vascular resistance induced by hemorrhagic shock in the anesthetized rat. J. Cardiovasc. Res., 26, S422-S424.
27. KLEMM, P., WARNER, T.D., HOHFELD, T., CORDER, R. & VANE, J.R. (1995a). Endothelin-1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc. Natl. Acad. Sci. U.S.A., 92, 2691-2695.
28. KLEMM, P., WARNER, T.D., CORDER, W.R. & VANE, J.R. (1995b). Endothelin-1 mediated coronary vasoconstriction caused by exogenous and endogenous cytokines. J. Cardiovasc. Pharmacol., 26, S419-S421.
29. KOLESNICK, R.N (1991). Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res., 30, 1-38.
30. LUMLEY, P., SEAGER, K. & WHITE, B. (1988). The TP-receptor blocking drugs GR32191 and BM13.177 have a differential profile of action on vascular smooth muscle. Br. J. Pharmacol., 95, 685P.
31. MATHISON, J.C., WOLFSON, E. & ULEVITCH, R.J. (1987). Participation of tumor necrosis factor in the mediation of gram negative bacterial lipipolysaccharide-induced injury in rabbits. J. Clin. Invest., 81, 1925-1937.
32. MERRILL, A.H., SCHMELZ, E.-M., DILLEHAY, D.L., SPIEGEL, S., SHAYMAN, J.A., SCHROEDER, RILEY, R.T., VOSS, K.A & WANG, E. (1997). Sphingolipids-the enigmatic lipid class: biochemistry, physiology and pathophysiology. Toxicol. Appl. Pharmacol., 142, 208-225.
33. MOZES, T., ZIJLSTRA, F.J., HEILIGERS, J.P.C., TAK, C.J.A.M., BENEFRAIM, S., BONTA, I.L. & SAXENA, P.R. (1991). Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs; protective effects on indomethacin. Br. J. Pharmacol., 104, 691-699.
34. MUROHARA, T., KUGIYAMA, K., OHGUSHI, M., SUGIYAMA, S., OHTA, Y. & YASUE, H. (1996). Effects of sphingomyelinase and sphingosine on arterial vasomotor regulation. J. Lipid. Res., 37, 1601-1608.
35. ORAL, H., DORN, G.W. & MANN, D.L. (1997). Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J. Biol. Chem., 272, 4836-4842.
36. POMPOSIELLO, S., YANG, X.P., LIU, Y.H., SURAKANTI, M., RHALEB, N.E., SEVILLA, M. & CARRETERO, O.A. (1997). Autocoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J. Cardiovasc. Pharmacol., 30, 599-606.
37. RAMACHANDRAN, C.K., MURRAY, D.K. & NELSON, D.H. (1992). Enzymatic hydrolysis of sphingomyelinase ion 3T3-L1 cells modulation by dexamethasone. Biochem. Archives, 8, 369-377.
38. REDL, H., SCHLAG, G., BAHRAMI, S., DAVIES, J., WAAGE, A., CESKA, M., BUURMAN, W.A. & ADOLF, G. (1993). The cytokine network in trauma and sepsis I: TNF and IL-8. In Pathophysiology of Shock, Sepsis and Organ Failure. ed. Schlag, G. & Redl, H. pp. 468-490. Berlin Heidelberg: Springer-Verlag.
39. SCHULZ, R., PANAS, D.L., CATENA, R., MONCADA, S., OLLEY, P.M. & LOPASCHUK, G.D. (1995). The role of nitric oxide in cardiodepression induced by interleukin-1β and tumour necrosis factor-α. Br. J. Pharmacol., 114, 27-34.
40. SCHULTZE, S., POTTHOFF, K., MACHLEIDT, T., BERKOVIC, D., WIEGMANN, K. & KRONKE, M. (1992). TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell, 71, 765-776.
41. SUGITA, M., WILLIAMS, M., DULANEY, J.T. & MOSER, H.W. (1975). Ceramidase and ceramide synthesis in human kidney and cerebellum. Biochem. Biophys. Acta, 398, 125-131.
42. TRACEY, K.J., BEUTLER, B., LOWRY, S.F., MERRYWEATHER, J., WOLPE, S., MILSARK, I.W., HARIRI, R.J., FAHEY III, T.J., ZENTELLA, A., ALBERT, J.D., SHIRES, G.T. & CERAMI, A. (1986). Shock and tissue injury induced by recombinant human cachectin. Science, 234, 470-474.
43. TRACEY, K.J., FONG, Y., HESSE, D.G., MANOGUE, K.R., LEE, A.T., KUO, G.C., LOWRY, S.F. & CERAMI, A. (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lathal bacteraemia. Nature, 330, 662-664.
44. VILCEK, J. & LEE, T.H. (1991). Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J. Biol. Chem., 266, 7317-7316.
45. YANG, Z., COSTANZO, M., GOLDE, D.W. & KOLESNICK, R.N. (1993). Tumor necrosis factor activation of the sphingomyelin pathway signals nuclear factor κB translocation in intact HL-60 cells. J. Biol. Chem., 268, 20520-20523.